Evidence map›Paper›PMID 42763655›Full record

ArticleIranian journal of pharmaceutical research : IJPR

Serine Protease Inhibitor 1 (SERPINE1) Regulates Epithelial-Mesenchymal Transition Gene Expression to Promote Migration and Invasion in Hepatocellular Carcinoma.

Run Bao, Zhaoxia Luo, Liao Gang, Wen Huang, Sheng Wu, Fangmin Xu

Abstract read
In one paragraph

Article in Iranian journal of pharmaceutical research : IJPR. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Run BaoDepartment of Gastroenterology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Zhaoxia LuoDepartment of Gastroenterology, The First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital), Shanghai 200433, China.
Liao GangDepartment of Gastroenterology, The First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital), Shanghai 200433, China.
Wen HuangDepartment of Gastroenterology, The First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital), Shanghai 200433, China.
Sheng WuDepartment of Gastroenterology, The First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital), Shanghai 200433, China.
Fangmin XuDepartment of Hepatobiliary Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hepatocellular carcinoma (HCC) is characterized by a high capacity for invasion and metastasis. Epithelial-mesenchymal transition (EMT) is a key mechanism that promotes tumor migration and invasion. However, the role of serine protease inhibitor 1 (SERPINE1) as a regulatory factor that may enhance tumor progression by directly modulating EMT-related gene expression in HCC has not been fully elucidated. Objectives: To investigate the role of SERPINE1 in regulating EMT-related gene expression and its effects on tumor invasion and migration in hepatocellular carcinoma (HCC). Methods: A comprehensive experimental approach integrating in vitro cell models, animal experiments, and clinical sample analyses was employed. qPCR, immunohistochemistry, and Western blotting were performed to determine SERPINE1 expression in HCC cell lines and tissues. SERPINE1 expression was modulated by RNA interference and overexpression, and the effects on HCC cell migration and invasion, as well as the expression of EMT markers, were evaluated. Results: SERPINE1 expression was approximately 3.2-fold and 2.8-fold higher in metastatic liver cancer cells and cancer tissues, respectively (P < 0.01). SERPINE1 expression was significantly negatively correlated with E-cadherin (r = -0.72) and positively correlated with vimentin (r = 0.65). After SERPINE1 knockdown, E-cadherin protein expression increased 2.1-fold, whereas N-cadherin and vimentin expression decreased by 68% and 55%, respectively; cell migration and invasion decreased by 62% and 57%, respectively (P < 0.01). Conversely, SERPINE1 overexpression reduced E-cadherin to 0.4-fold of the control level, whereas N-cadherin and vimentin increased 2.3-fold and 2.0-fold, respectively, and migration and invasion increased 1.9-fold and 2.1-fold, respectively. In the in vivo orthotopic lung metastasis model, SERPINE1 knockdown reduced the number of lung metastatic foci from 4.8 ± 1.1 to 1.5 ± 0.6 (P < 0.01), and the incidence of metastasis decreased from 83.3% to 33.3%. Mechanistic studies revealed that, after SERPINE1 knockdown, the p-AKT/AKT and p-ERK/ERK ratios decreased by 64% and 57%, respectively, and the EMT transcription factors Snail and Slug were downregulated; PI3K agonists partially reversed the inhibition of the EMT phenotype. These results suggest that SERPINE1 activates the PI3K/AKT and MAPK signaling pathways, upregulates EMT-related gene expression, and thereby promotes liver cancer cell migration, invasion, and lung metastasis. Conclusions: SERPINE1 facilitates the migration and invasion of HCC cells by modulating EMT-related gene expression. SERPINE1 is upregulated in liver cancer tissues and may contribute to liver cancer progression.

Indexed as

Epithelial–mesenchymal Transition (EMT)Hepatocellular Carcinoma (HCC)Migration and InvasionSerine Protease Inhibitor 1 (SERPINE1)

Identifiers

PMID42763655
PMCPMC13589458

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.